Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, and found statistically significant relative reduction in cardiovascular risk in people consuming omega-3 fatty acids. Areas covered: This article reviews studies on omega-3 fatty acids during the last 50 years, and identifies issues relevant to future studies on cardiovascular (CV) risk. Expert commentary: Although a meta-analysis of large-scale prospective cohort studies and randomized studies reported that fish and fish oil consumption reduced coronary heart disease-related mortality and sudden cardiac death, omega-3 fatty acids have not yet been shown to be effective in secondary prevention trials on patients with multiple cardiovascular disease (CVD) risk factors. The ongoing long-term CV interventional outcome studies investigate high-dose, prescription-strength omega-3 fatty acids. The results are expected to clarify the potential role of omega-3 fatty acids in reducing CV risk. The anti-inflammatory properties of omega-3 fatty acids are also important. Future clinical trials should also focus on the role of these anti-inflammatory mediators in human arteriosclerotic diseases as well as inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · cited 1×
“and suppresses cytokine production, thereby leading to resolution of acute inflammation [91].”
BackgroundFish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650
(2015) · The Lancet · doi:10.1016/s0140-6736(14)61368-4 · Cited by 1,536 · cited 1×
“The efficacy of statin for both primary and secondary prevention of CVD has been established [97], and LDL-C-lowering therapy with statin has been used as the first-line treatment.”
BackgroundTriglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014682.14181.f2 · Cited by 1,311
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Research works printed but not linked: 62
- 10.1001/jama.2009.1178 · DOI · Paper page
- Kimura N, 1970, Circulation, 41, I101
- Bang HO, 1976, Acta Med Scand, 200, 69, 10.1111/j.0954-6820.1976.tb08198.x · DOI · Paper page
- Sinclair HM, 1952, Br J Nutr, 12, 69
- Parkinson AJ, 1994, Am J Clin Nutr, 59, 384, 10.1093/ajcn/59.2.384 · DOI
- 10.1016/0021-9150(83)90181-8 · DOI · Paper page
- 10.1016/j.jacl.2013.09.002 · DOI
- 10.2459/01.JCM.0000289269.98105.65 · DOI
- Nordoy A, 1991, Am J Clin Nutr, 53, 1185, 10.1093/ajcn/53.5.1185 · DOI
- 10.1016/S0002-9149(96)00159-2 · DOI · Paper page
- 10.2146/ajhp060164 · DOI · Paper page
- 10.1586/14779072.6.3.391 · DOI · Paper page
- 10.1016/j.jacl.2014.02.036 · DOI
- 10.1111/1755-5922.12146 · DOI
- 10.1016/j.amjcard.2005.12.026 · DOI · Paper page
- 10.1016/j.atherosclerosis.2012.01.006 · DOI · Paper page
- 10.1016/j.atherosclerosis.2013.10.014 · DOI · Paper page
- 10.1016/j.jnutbio.2014.02.004 · DOI
- 10.1016/j.numecd.2016.07.012 · DOI
- 10.1016/j.prostaglandins.2015.05.003 · DOI
- 10.1007/s11745-001-0692-x · DOI · Paper page
- 10.1016/j.jjcc.2014.01.005 · DOI
- 10.1172/JCI110288 · DOI · Paper page
- Chang KJ, 1991, J Leukoc Biol, 50, 273, 10.1002/jlb.50.3.273 · DOI
- 10.1007/BF01966464 · DOI
- 10.1016/j.atherosclerosis.2008.07.045 · DOI
- 10.1016/j.atherosclerosis.2007.07.023 · DOI
- 10.4049/jimmunol.0903282 · DOI
- 10.1053/ajkd.2001.27392 · DOI · Paper page
- 10.1056/NEJM197403282901301 · DOI · Paper page
- 10.4103/2279-042X.192451 · DOI
- 10.1001/2012.jama.11374 · DOI · Paper page
- 10.1016/j.atherosclerosis.2013.11.073 · DOI
- 10.1161/JAHA.113.000506 · DOI · Paper page
- 10.1016/j.amepre.2016.07.020 · DOI
- Gobbo LCD, 2016, JAMA Intern Med, 94305, 1
- 10.1161/01.CIR.0000055315.79177.16 · DOI · Paper page
- 10.1016/j.mayocp.2016.10.018 · DOI · Paper page
- 10.1016/j.mayocp.2016.11.008 · DOI
- 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
- 10.1016/j.atherosclerosis.2013.11.048 · DOI
- 10.1177/2047487313517576 · DOI
- 10.1161/01.CIR.0000031732.78052.81 · DOI · Paper page
- 10.1016/j.atherosclerosis.2015.02.033 · DOI
- Malik AR, 2007, J Hum Hypertens, 21, 231, 10.1038/sj.jhh.1002143 · DOI
- 10.1681/ASN.2005121288 · DOI · Paper page
- 10.1186/1476-511X-9-7 · DOI
- 10.1016/j.jacc.2005.03.038 · DOI · Paper page
- 10.1161/CIRCHEARTFAILURE.110.960450 · DOI · Paper page
- 10.1093/eurjhf/hfq172 · DOI · Paper page
- 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
- 10.1001/jama.295.22.2613 · DOI · Paper page
- 10.1161/JAHA.112.005033 · DOI · Paper page
- 10.1038/ejcn.2012.133 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.115.019949 · DOI · Paper page
- 10.1152/ajpheart.01057.2009 · DOI · Paper page
- 10.1016/j.yjmcc.2015.04.003 · DOI · Paper page
- 10.1084/jem.20132011 · DOI · Paper page
- 10.5551/jat.ED063 · DOI
- 10.1016/j.atherosclerosis.2013.09.023 · DOI
- 10.1016/j.amjcard.2012.08.038 · DOI
- 10.1002/fsn3.121 · DOI · Paper page
Cited by
Impact of Omega-3 Fatty Acids on the Gut Microbiota
Costantini, L., Molinari, R., Farinon, B., & Merendino, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122645 · Cited by 741
“Also, with regards to the link to immunity, studies have shown that the supplementation of omega-3 PUFAs provides multiple health benefits against different chronic degenerative diseases, such as cardiovascular diseases [7], rheumatoid arthritis [8], inflammatory bowel disease (IBD) [9], depression [10], and cancer [1…”
BackgroundCyanobacteria and microalgae in supporting human habitation on Mars
Mapstone, L. J., Leite, M. N., Purton, S., Crawford, I. A., & Dartnell, L. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.107946 · Cited by 92
“…roles in metabolism, including promoting brain health and reducing neuropsychiatric disorders (Derbyshire, 2018; Reimers and Ljung, 2019), aiding in immune system signalling (Guti ´ errez et al., 2019) and maintaining the cardiovascular system (Pizzini et al., 2018; Watanabe and Tatsuno, 2017).”
Casula, M., Olmastroni, E., Gazzotti, M., Galimberti, F., Zambon, A., & Catapano, A. L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105060 · Cited by 54
Technological readiness of commercial microalgae species for foods
Yang, S., Fan, Y., Cao, Y., Wang, Y., Mou, H., & Sun, H. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2194423 · Cited by 47
Metadata
- Authors
- Watanabe, Y., & Tatsuno, I.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2017-05-29
- Volume
- 10
- Issue
- 8
- Pages
- 865-873
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2614919993
- Cited by
- 93
- References
- 40
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Eli Lilly and Company (no number)
- Mochida Pharmaceutical Company (no number)
- Takeda Pharmaceutical Company (no number)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.